Investigational drug · Phase 2
AC591
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Adenoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AC591"
First trial start
2024
Dec 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AC591", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Adenoma
Largest trials
Live from ClinicalTrials.gov: studies naming "AC591" as an intervention, largest first.
- Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral NeuropathyPivotal-lookingNot yet recruiting
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT06722950 · 120 participants (planned) · Start Dec 2024 · Primary completion Dec 2026
Drug: CAPEOX; Placebo and 1 more · For: Colorectal Adenoma
Newest research
PubMed records naming it or its code names, newest first.
- Herbal Formula AC591 Protects Against Cisplatin-Induced Hearing Loss by Inhibiting p53-Mediated Ferroptosis.
Wu Y, Tao Y, Wei L, et al. · Smart Med 2026
- Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients.
Cheng X, Huo J, Wang D, et al. · Front Pharmacol 2017
Also in development for Colorectal Adenoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.